Theriva Biologics, Inc. (TOVX)

Over the past six months, Theriva Biologics' stock price has been impacted by a positive FDA meeting for VCN-01, the release of full-year 2025 financial results, a SYN-020 licensing agreement, an upcoming presentation of VCN-01 data, warrant-related transactions, and a stock price decline. The stock has experienced a significant decline, losing 49.57% over the past six months and 76.2% over the past 12 months.

Information regarding demand seasonality for Theriva Biologics, Inc.'s products and services is not available. As a clinical-stage biotechnology company, its revenue model is likely built on licensing agreements, research collaborations, and eventual commercialization of its therapies, rather than products with typical consumer demand seasonality.

Theriva Biologics, Inc. is a clinical-stage biotechnology company focused on developing therapeutics for cancer and related diseases, with an emphasis on oncology and microbiome preservation. The company's major product candidates include VCN-01, an oncolytic adenovirus; SYN-004 (ribaxamase), an oral prophylactic therapy; and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP).

Theriva Biologics, Inc. is headquartered in Rockville, Maryland, United States. The company also has operations in Spain through its subsidiary, Theriva Biologics, S.L., which conducts research and clinical development activities related to its oncolytic adenovirus platform.

In the past year, Theriva Biologics' brand reputation has been influenced by its clinical development progress and financial activities. Positive developments, such as the favorable End-of-Phase 2 meeting with the FDA for VCN-01 in metastatic pancreatic cancer, contribute positively to its reputation. However, the significant decline in its stock price over the past year could negatively impact investor confidence. The company's focus on addressing high unmet medical needs in oncology and infectious diseases generally supports a positive reputation within the healthcare sector.

Theriva Biologics (TOVX) stock ownership is primarily held by retail investors, who own approximately 96.63% to 98.61% of the company. Major institutional owners include Vanguard Group Inc, Geode Capital Management LLC, Morgan Stanley, UBS Group AG, Ikarian Capital, LLC, Two Sigma Securities, Llc, Two Sigma Investments, Lp, DRW Securities, LLC, XTX Topco Ltd and StoneX Group Inc. The largest individual shareholder is Steven A. Shallcross, who owns 250,000 shares, representing 0.54% of the company.